Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 469

1.

Social and functional outcomes with two doses of aripiprazole lauroxil vs placebo in patients with schizophrenia: a post-hoc analysis of a 12-week phase 3 efficacy study.

Correll CU, Stanford AD, Claxton A, Du Y, Weiden PJ.

Psychiatry Res. 2019 Apr;274:176-181. doi: 10.1016/j.psychres.2019.02.021. Epub 2019 Feb 14.

2.

Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.

Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S.

J Clin Psychiatry. 2018 Dec 18;80(1). pii: 18m12294. doi: 10.4088/JCP.18m12294.

PMID:
30695291
3.

Serum Level Measurements Optimize Aripriprazole Treatment in Adolescent Patients.

Gehrmann J, Götz Lampe P.

Z Kinder Jugendpsychiatr Psychother. 2019 May;47(3):261-264. doi: 10.1024/1422-4917/a000637. Epub 2018 Dec 5.

4.

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.

Schöttle D, Janetzky W, Luedecke D, Beck E, Correll CU, Wiedemann K.

BMC Psychiatry. 2018 Nov 14;18(1):365. doi: 10.1186/s12888-018-1946-x. Erratum in: BMC Psychiatry. 2018 Dec 14;18(1):389.

5.

Long-Term Antipsychotic Effectiveness in First Episode of Psychosis: A 3-Year Follow-Up Randomized Clinical Trial Comparing Aripiprazole, Quetiapine, and Ziprasidone.

Gómez-Revuelta M, Pelayo-Terán JM, Juncal-Ruiz M, Ortiz-García de la Foz V, Vázquez-Bourgon J, González-Pinto A, Crespo-Facorro B.

Int J Neuropsychopharmacol. 2018 Dec 1;21(12):1090-1101. doi: 10.1093/ijnp/pyy082.

6.

Aripiprazole/Methylphenidate Combination in Children and Adolescents with Disruptive Mood Dysregulation Disorder and Attention-Deficit/Hyperactivity Disorder: An Open-Label Study.

Pan PY, Fu AT, Yeh CB.

J Child Adolesc Psychopharmacol. 2018 Dec;28(10):682-689. doi: 10.1089/cap.2018.0068. Epub 2018 Aug 27.

PMID:
30148656
7.
8.

The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.

Calabrese JR, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, Perry PP, Hertel P, Such P, McQuade RD, Nyilas M, Carson WH.

J Affect Disord. 2018 Dec 1;241:425-432. doi: 10.1016/j.jad.2018.06.043. Epub 2018 Jul 6.

9.

Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy.

Ostuzzi G, Mazzi MA, Terlizzi S, Bertolini F, Aguglia A, Bartoli F, Bortolaso P, Callegari C, Caroleo M, Carrà G, Corbo M, D'Agostino A, Gastaldon C, Lucii C, Magliocco F, Martinotti G, Nosé M, Ostinelli EG, Papola D, Piccinelli MP, Piccoli A, Purgato M, Tabacchi T, Turrini G, Ruggeri M, Barbui C; STAR Network Investigators.

PLoS One. 2018 Aug 2;13(8):e0201371. doi: 10.1371/journal.pone.0201371. eCollection 2018.

10.

Aripiprazole Lauroxil NanoCrystal® Dispersion Technology (Aristada Initio®).

Ehret MJ, Davis E, Luttrell SE, Clark C.

Clin Schizophr Relat Psychoses. Summer 2018;12(2):92-96. doi: 10.3371/CSRP.EHDA071918.

PMID:
30040476
11.

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia.

Hard ML, Wehr AY, Du Y, Weiden PJ, Walling D, von Moltke L.

J Clin Psychopharmacol. 2018 Oct;38(5):435-441. doi: 10.1097/JCP.0000000000000921.

12.

Clinical Predictors of Extrapyramidal Symptoms Associated With Aripiprazole Augmentation for the Treatment of Late-Life Depression in a Randomized Controlled Trial.

Hsu JH, Mulsant BH, Lenze EJ, Sanches M, Karp JF, Reynolds CF, Blumberger DM.

J Clin Psychiatry. 2018 Jun 19;79(4). pii: 17m11764. doi: 10.4088/JCP.17m11764.

PMID:
29924506
13.

Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial.

Kelly DL, Powell MM, Wehring HJ, Sayer MA, Kearns AM, Hackman AL, Buchanan RW, Nichols RB, Adams HA, Richardson CM, Vyas G, McMahon RP, Earl AK, Sullivan KM, Liu F, Luttrell SE, Dickerson FB, Feldman SM, Narang S, Koola MM, Buckley PF, RachBeisel JA, McEvoy JP.

J Clin Psychopharmacol. 2018 Aug;38(4):317-326. doi: 10.1097/JCP.0000000000000898.

14.

Metabolic Effects of Antipsychotics on Adiposity and Insulin Sensitivity in Youths: A Randomized Clinical Trial.

Nicol GE, Yingling MD, Flavin KS, Schweiger JA, Patterson BW, Schechtman KB, Newcomer JW.

JAMA Psychiatry. 2018 Aug 1;75(8):788-796. doi: 10.1001/jamapsychiatry.2018.1088.

15.

Safety and efficacy from a 6-week double-blind study and a 52-week open-label extension of aripiprazole in adolescents with schizophrenia in Japan.

Matsumoto H, Ishigooka J, Ono H, Tadori Y.

Psychiatry Clin Neurosci. 2018 Sep;72(9):701-712. doi: 10.1111/pcn.12681. Epub 2018 Jul 2.

16.

PLACID study: A randomized trial comparing the efficacy and safety of inhaled loxapine versus intramuscular aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.

San L, Estrada G, Oudovenko N, Montañés F, Dobrovolskaya N, Bukhanovskaya O, Popov M, Vieta E.

Eur Neuropsychopharmacol. 2018 Jun;28(6):710-718. doi: 10.1016/j.euroneuro.2018.03.010. Epub 2018 May 1.

17.

Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants.

Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Jiang-Zheng C, Koller D, Mejía G, Zubiaur P, Wojnicz A, Abad-Santos F.

Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):474-485. doi: 10.1111/bcpt.13031. Epub 2018 Jun 13.

18.

Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.

Augusto M, Greene M, Touya M, Sweeney SM, Waters H.

J Comp Eff Res. 2018 Jul;7(7):637-650. doi: 10.2217/cer-2018-0010. Epub 2018 Apr 25.

19.

Aripiprazole as an adjuvant treatment for obsessive and compulsive symptoms in manic phase of bipolar disorder: A randomized, double-blind, placebo-controlled clinical trial.

Sahraian A, Ehsaei Z, Mowla A.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Jun 8;84(Pt A):267-271. doi: 10.1016/j.pnpbp.2018.03.014. Epub 2018 Mar 12.

PMID:
29544694
20.

Dried Blood Spot Analysis for Therapeutic Drug Monitoring of Antipsychotics: Drawbacks of Its Clinical Application.

Kloosterboer SM, de Winter BCM, Bahmany S, Al-Hassany L, Dekker A, Dieleman GC, van Gelder T, Dierckx B, Koch BCP.

Ther Drug Monit. 2018 Jun;40(3):344-350. doi: 10.1097/FTD.0000000000000502.

PMID:
29505492

Supplemental Content

Loading ...
Support Center